A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer

  • STATUS
    Recruiting
  • End date
    Nov 26, 2021
  • participants needed
    25
  • sponsor
    Vaxiion Therapeutics
Updated on 26 January 2021
platelet count
cancer
absolute neutrophil count
tumor cells
bladder cancer
invasive bladder cancer

Summary

The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for Instillation (VAX014) in patients with low-grade Non-Muscle Invasive Bladder Cancer (NMIBC). VAX014 is a targeted oncolytic agent designed to kill tumor cells following instillation into the urinary bladder.

Description

This study will evaluate the safety and tolerability of VAX014 using a 3+3 dose escalation design to determine a maximum tolerated dose (MTD) followed by a dose expansion at the Recommended Phase 2 Dose (RP2D). Both phases of the study will use a Window of Opportunity study design where patients with a single, low-grade Ta lesion will receive VAX014 via a urinary catheter into the bladder, weekly for 6 weeks prior to undergoing Transurethral Resection of Bladder Tumor (TURBT) to assess antitumor activity against the mapped lesion.

Patients enrolled in this study must have low-grade (Ta) Non-Muscle Invasive Bladder Cancer. However, eligible patients may have up to 5 low-grade Ta lesions at screening, and all but a single mapped lesion will be resected prior to receiving VAX014. The mapped lesion is assessed for anti-tumor activity.

VAX014 is a formulation of recombinant bacterial minicells which is designed to selectively target two NMIBC-associated integrin heterodimers to de-stabilize tumor cell membranes, with the result being tumor cell lysis.

Details
Condition Transitional Cell Carcinoma of the Bladder, Urothelial Carcinoma of the Urinary Bladder, transitional cell carcinoma of bladder
Treatment VAX014
Clinical Study IdentifierNCT03854721
SponsorVaxiion Therapeutics
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Urothelial Carcinoma of the Urinary Bladder?
Do you have any of these conditions: Urothelial Carcinoma of the Urinary Bladder or Transitional Cell Carcinoma of the Bladder or transitional cell carcinoma of bladder?
Do you have any of these conditions: transitional cell carcinoma of bladder or Urothelial Carcinoma of the Urinary Bladder or Transitional Cell Carcinoma of the Bladder?
Do you have any of these conditions: Urothelial Carcinoma of the Urinary Bladder or transitional cell carcinoma of bladder or Transitional Cell Carcinoma of the Bladder?
Signed, informed consent
Age 18 or more years
Pathologically confirmed low-grade Ta urothelial carcinoma (UC) of the urinary bladder
NMIBC with one solitary measurable tumor at the start of study, measuring 5 mm and 15 mm in greatest diameter (up to 4 additional low-grade Ta lesions, each measuring no more than 15 mm may be removed at screening provided a single lesion remains)
Treatment-nave or failed one previous regimen of intravesical therapy (BCG or chemotherapy)
If recurrent disease, then more than 6 months from prior resection, more than 3 months from completion of last intravesical therapy with BCG, and more than 6 weeks from completion of last therapeutic intravesical therapy with chemotherapy
If previously treated, recovered from prior treatment-related toxicity to Grade 1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 116
Absolute neutrophil count (ANC) 1,500/mm3
Platelet count 100,000/mm3
Total bilirubin 1.5 x upper limit of normal (ULN), or 3 x ULN in subjects with Gilberts disease
Serum creatinine 1.5 x ULN or creatinine clearance 30 mL/min
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) 2.5 x ULN
Willingness to participate in collection of pharmacokinetic samples
Women of childbearing potential must have a negative serum pregnancy test
All subjects of childbearing potential must be willing to use effective contraception while on treatment and for 3 months after the last dose of VAX014

Exclusion Criteria

Additional papillary disease at screening (in addition to the solitary low-grade Ta lesion detailed in the inclusion criteria) that
Consist of 6 or more lesions
Consists of any lesion with a maximal diameter of greater than 15 mm
Confirmed or suspected perforated bladder
History of difficult catheterization that in the opinion of the investigator will prevent administration of VAX014
Presence or history of any high-grade urothelial cancer (including CIS) or high-grade urine cytology
Intravesical chemo-or biological therapy within 6 months of first administration of VAX014
UC of the ureters or urethra
History of interstitial cystitis
History of radiation to the pelvis
History of vesicoureteral reflux or an indwelling urinary stent
Other known active cancer(s) likely to require treatment or interfere with study objectives over the next two (2) years
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Known HIV, Hepatitis B, or Hepatitis C infection
Significant cardiovascular risk (e.g., coronary stenting within 8 weeks, myocardial infarction within 6 months)
Major surgery other than diagnostic surgery within 4 weeks of first administration of VAX014
Pregnant or currently breast-feeding
Psychiatric illness/social situations that would interfere with compliance with study requirements
Presence of any sessile appearing tumor suspected of being invasive or high-grade
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note